Meet us at the Targeted Radiopharmaceuticals Summit 2022
Minerva Imaging will be presenting at the 4th Annual Targeted Radiopharmaceuticals Summit, 6-8 December in Amsterdam, the Netherlands. Please join our co-founders Carsten H. Nielsen, CEO, and Andreas Kjaer, CSO, during their presentation about Minerva Imaging’s fast and integrated development of next generation radiopharmaceuticals.
If you are interested in learning more about our services or set up a meeting during the congress, please feel free to contact Fabian Pruissen, Business Developer.
About Minerva Imaging
Minerva Imaging is a scientifically driven CRO focused on targeted radionuclide therapy with the use of advanced oncology models and molecular imaging for translational cancer research and drug development.
With over 10 years of experience in targeted radiopharmaceuticals, we are experts in designing and performing preclinical targeted radionuclide therapy studies. We operate a state-of-the-art facility with on-site radiochemistry, cell and in vitro laboratories, in vivo facilities for both small and large animals, all certified to work with diagnostic and therapeutic radioisotopes. This year we initiated a 1500 square meter expansion worth over 20M USD. The investment in Contract Development and Manufacturing services (CDMO) adds GMP manufacturing of radionuclides and radiopharmaceuticals to Minerva’s chain of services.
We engage with our clients to understand their scientific questions and discuss how our methods and capabilities can provide answers. Our competences build on more than two decades of research within oncology, targeted radionuclide therapy and molecular imaging performed at the University of Copenhagen and Rigshospitalet, the National University Hospital of Denmark.